Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2018-01-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mesenchymal Stromal Cells
Mesenchymal Stromal Cells
Suspension of mesenchymal stromal cells for intratissular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesenchymal Stromal Cells
Suspension of mesenchymal stromal cells for intratissular injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signing the informed consent
* Diagnosis of Crohn Disease for more than 6 months
* Presence of at least one Crohn Disease lesion refractory to conventional therapies (azathioprine, 6-mercaptopurine or methotrexate) and to biologic treatments (anti-Tumor Necrosis Factor therapies, vedolizumab, or ustekinumab).
* Refractory lesion defined by (1) a stricture with a length of 2 to 5cm of the colon or the ileum accessible by ileocolonoscopy (i.e. a lesion identified during a colonoscopy with a lumen narrowing non passable by the colonoscope), (2) unhealed deep ulcer of the colon or the ileum accessible to ileocolonoscopy, or (3) actively draining perianal fistula(s).
* Twenty patients with stricture(s), 20 patients with unhealed deep ulcer(s), and 20 patients with an actively draining perianal fistula(s) will be included
Exclusion Criteria
* Intestinal obstruction
* Intra-abdominal fistulas or abscess
* Intestinal/colonic stricture or deep unhealed ulcer not accessible to ileocolonoscopy
* Undrained peri-anal abscess
* Pregnant women or planning pregnancy within one year
* Positive stool culture/toxin for clostridium difficile pathogen or other pathogens
* Renal failure (anuria, serious fluid overload, Glomerular Filtration Rate \< 30 ml/min, dialysis) or hepatic failure (Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \>3 mg/dL)
* documented human immunodeficiency virus infection; active hepatitis B, C, or tuberculosis
* an opportunistic infection within 6 months before screening or a serious infection in the previous 3 months
* malignancy within the past 5 years; or a history of lymphoproliferative disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Liege
OTHER
University of Liege
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edouard Louis
Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edouard Louis, Prof
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Liege
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Liège
Liège, Liège, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Edouard Louis, Prof
Role: primary
Layla Boutaffala
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJT1707P1
Identifier Type: -
Identifier Source: org_study_id